Klebsiella pneumoniae infections are treated with antibiotics, but the specific drugs depend entirely on where the infection is in your body and whether the bacteria are resistant to common medications. Most standard strains respond well to widely available antibiotics, while drug-resistant strains require newer, specialized medications that are typically given through an IV in a hospital setting. Getting the right antibiotic matched to the specific strain is the single most important factor in successful treatment.
How Doctors Identify the Right Antibiotic
Before treatment can be tailored, your medical team needs to know exactly which strain you’re dealing with and what drugs it responds to. This starts with collecting a sample, whether that’s blood, urine, sputum, or fluid from a wound, and sending it to a lab for culture. Traditional methods like microscopy and biochemical identification are reliable but time-consuming. Newer molecular tests based on PCR technology can identify Klebsiella within about an hour, though the full antibiotic sensitivity results from a culture typically take one to three days.
During that waiting period, doctors usually start empiric therapy, meaning they choose an antibiotic based on their best guess of what will work given local resistance patterns. Once sensitivity results come back, they may switch to a more targeted drug. This adjustment matters: carbapenem-resistant strains carry roughly four times the mortality risk of non-resistant strains in bloodstream infections, so landing on the right antibiotic quickly makes a real difference.
Treatment for Standard (Non-Resistant) Strains
When the bacteria respond to common antibiotics, treatment is straightforward. Urinary tract infections caused by susceptible Klebsiella are often treated with oral antibiotics for 5 to 10 days. Pneumonia or bloodstream infections typically require IV antibiotics in a hospital, with courses ranging from 7 to 14 days depending on severity. The specific drug class your doctor chooses will depend on the infection site, but for susceptible strains, options are plentiful and outcomes are generally good.
Drug-Resistant Klebsiella: ESBL-Producing Strains
Some Klebsiella strains produce enzymes called extended-spectrum beta-lactamases (ESBLs) that break down many standard antibiotics before they can work. ESBL-producing strains are a step up in difficulty. They resist most penicillin-type and cephalosporin-type drugs, which narrows the options considerably. A class of antibiotics called carbapenems has traditionally been the go-to treatment for these infections.
ESBL-producing Klebsiella bloodstream infections carry roughly 1.5 to 1.8 times the mortality risk compared to non-ESBL strains, based on a large meta-analysis. This higher risk is partly because patients often receive the wrong antibiotic initially before sensitivity results confirm the ESBL pattern.
Carbapenem-Resistant Klebsiella: The Hardest to Treat
The most concerning strains are carbapenem-resistant, meaning they’ve developed defenses against even the powerful backup antibiotics. These infections are serious. A systematic review found that bloodstream infections caused by carbapenem-resistant Klebsiella had 30-day mortality around 29%, and the risk of death was nearly four times higher than with carbapenem-susceptible strains.
For these infections, the 2024 Infectious Diseases Society of America (IDSA) guidance recommends newer combination antibiotics that pair a traditional drug with a compound designed to disable the bacteria’s resistance mechanism. The preferred options include ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam. These drugs are given intravenously, typically every 6 to 8 hours, with treatment courses of 5 to 14 days depending on the infection type and severity.
If the bacteria resist even these newer combinations, a drug called cefiderocol serves as a further backup. Approved by the FDA in 2020, cefiderocol uses an unusual strategy: it’s designed to mimic a molecule bacteria use to absorb iron, essentially tricking the bacteria into pulling the antibiotic inside. This “Trojan horse” approach allows it to bypass many of the defenses that block other drugs. The IDSA guidelines recommend against adding a second antibiotic on top of these newer agents when the bacteria test susceptible to them, since combination therapy hasn’t shown added benefit in that scenario.
Treatment Duration by Infection Type
How long treatment lasts depends on where the infection is:
- Urinary tract infections: 5 to 10 days for most of the newer agents. Some complicated cases, particularly those involving resistant strains, may require up to 14 days.
- Pneumonia: Typically 7 to 14 days, though hospital-acquired pneumonia on a ventilator may need the longer end of that range.
- Bloodstream infections: Usually 10 to 14 days, sometimes longer if the source of the infection (like an abscess or infected device) hasn’t been fully addressed.
Source control matters as much as the antibiotics themselves. If there’s an infected catheter, drain, or implant involved, removing or replacing it dramatically improves the odds of clearing the infection.
What Hospitalization Looks Like
Resistant Klebsiella infections almost always require hospital treatment with IV antibiotics. If your strain is classified as a multidrug-resistant organism, the hospital will likely place you on contact precautions. This means healthcare workers wear gloves and gowns when entering your room, and you may be in a private room or grouped with other patients who have similar organisms. These measures protect other patients, especially those with weakened immune systems.
Standard, non-resistant Klebsiella pneumonia doesn’t require special isolation beyond the usual hygiene practices. The level of precaution is determined by the infection control team based on the resistance profile of your specific strain and local transmission patterns.
Why Outcomes Vary So Widely
Klebsiella bloodstream infections have an overall in-hospital mortality of about 29%, but that number masks enormous variation. Patients with susceptible strains who receive appropriate antibiotics early do far better than those with resistant strains where effective treatment is delayed. A meta-analysis of Klebsiella bacteremia found that 30-day mortality climbed from around 24% at two weeks to 34% by 90 days, reflecting the toll of prolonged illness on patients who are often already seriously unwell.
The factors that most influence your outcome include the resistance profile of the strain, how quickly you receive an effective antibiotic, whether the source of the infection can be controlled, and your overall health going in. People with compromised immune systems, those on ventilators, or those with recent surgeries face higher risks. Getting infectious disease specialists involved early, which the IDSA explicitly recommends for antimicrobial-resistant infections, improves the chances that the right drug is chosen from the start.
Phage Therapy and Experimental Approaches
Bacteriophage therapy, which uses viruses that specifically target and kill bacteria, is being studied as a potential treatment for resistant Klebsiella. Clinical trials are in early stages. A Phase 1 trial at UC San Diego is evaluating IV phage therapy combined with standard antibiotics in cystic fibrosis patients with resistant lung infections, though it is not yet enrolling patients. Phage therapy is not currently available as a standard treatment option outside of compassionate use or clinical trials.